Vacc-4x: Additional Phase I/II data

Data from 17 evaluable patients with HIV-1 infection in Part B of the open-label, Danish Phase I/II REDUC trial showed that Vacc-4x plus GM-CSF adjuvant followed by 5 mg/m 2 IV Istodax romidepsin -- a histone deacetylase (HDAC) inhibitor from Celgene Corp. (NASDAQ:CELG, Summit, N.J.) -- once a week for 3 weeks significantly reduced the latent HIV reservoir by 40% as measured by both total HIV DNA (p=0.012) and by HIV quantitative viral outgrowth assay (qVOA) (p=0.019). Viral load remained below the level of detection (20 copies/mL) in 11 patients on cART despite reservoir reactivation. ...